Would you offer adjuvant chemotherapy to a woman in her 40's s/p TAHBSO with T2N1 ER+/PR+ breast cancer with oncotype score 21-25?  

How much of the benefit of adjuvant chemotherapy do you expect to be due to ovarian function suppression due to the chemotherapy?



Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty
RxPONDER trial overall included 10.3% patients wit...
Medical Oncologist at Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty
There is a recent article on this topic just to sh...
Sign in or Register to read more